H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer

32Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Antiandrogen strategies remain the prostate cancer treatment backbone, but drug resistance develops. We show that androgen blockade in prostate cancer leads to derepression of retroelements (REs) followed by a double-stranded RNA (dsRNA)-stimulated interferon response that blocks tumor growth. A forward genetic approach identified H3K9 trimethylation (H3K9me3) as an essential epigenetic adaptation to antiandrogens, which enabled transcriptional silencing of REs that otherwise stimulate interferon signaling and glucocorticoid receptor expression. Elevated expression of terminal H3K9me3 writers was associated with poor patient hormonal therapy outcomes. Forced expression of H3K9me3 writers conferred resistance, whereas inhibiting H3K9-trimethylation writers and readers restored RE expression, blocking antiandrogen resistance. Our work reveals a drug resistance axis that integrates multiple cellular signaling elements and identifies potential pharmacologic vulnerabilities.

Cite

CITATION STYLE

APA

Baratchian, M., Tiwari, R., Khalighi, S., Chakravarthy, A., Yuan, W., Berk, M., … Sharifi, N. (2022). H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 119(21). https://doi.org/10.1073/pnas.2114324119

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free